BioWorld

Sep. 27, 2010

View Archived Issues

What T-DM1 Means for Roche And Biotechs on the AA Path

Read More

Firms Opt for Regional Deals on Road to Larger Markets

Read More

Money Raised Year to Date

Read More

Money Raised By Biotech in 2010

Read More

Week in Review

Read More

Week in Washington

Read More

Word on the Street

Read More

U.S. Public Offering Performance By Underwriter: Jan. 1 - Aug. 31, 2010

Read More

Underwriters' Performance on IPOs: Jan. 1 - Aug. 31, 2010

Read More

Underwriters' Performance on IPOs: Jan. 1 – Aug. 31, 2010

Read More

Lead Underwriter Performance on All U.S. Offerings: Jan. 1 – Aug. 31, 2010

Read More

Stock Gainers and Losers For The Week

Read More

BioWorld Stock Report For Public Biotechnology Companies

Read More

Debate Sparked Over Recent Rulings, but What's Changed?

After 17 years of smooth sailing – Iressa (gefitinib, AstraZeneca plc) notwithstanding – the FDA's accelerated approval process seems to have hit some choppy waters. Read More